Company profile: Theraclone Sciences
1.1 - Company Overview
Company description
- Provider of novel therapeutic antibodies and an antibody discovery platform for infectious diseases and inflammation. Offers a comprehensive screening technology to identify rare human monoclonal antibodies, HIV broadly neutralizing fully human antibodies licensed to Gilead for HIV-cure regimens, and platform technology licensed to OncoResponse for oncology.
Products and services
- HIV Broadly Neutralizing Fully-Human Antibodies: Clinical-grade antibodies licensed to Gilead for development as part of an HIV-cure regimen, delivering broad neutralization characteristics to support curative strategies in infections
- Licensed Platform Technology to OncoResponse: Validated platform technology licensed to OncoResponse for use in oncology, leveraging the platform’s ability to identify rare human monoclonal antibodies for oncology applications
- Platform Technology: High-throughput screening system that identifies rare human monoclonal antibodies evolved to cure infections and fight diseases, supporting discovery of candidates for infectious diseases and inflammation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theraclone Sciences
Mevion Medical Systems
HQ: United States
Website
- Description: Provider of innovative, safe, and effective radiation therapy solutions for the treatment of cancer, pioneering modern proton therapy systems and transforming advances in medical technology and science into practical clinical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mevion Medical Systems company profile →
Aurealis Therapeutics
HQ: Finland
Website
- Description: Provider of cell and gene therapies for chronic wounds and complex inflammatory diseases. Its four-in-one biologic AUP-16 is a genetically engineered Lactococcus cremoris producing therapeutic proteins to halt inflammation, induce blood vessel growth, and promote tissue formation for diabetic foot, venous leg, and pressure ulcers. AUP-55 is in pre-clinical development for ovarian and bladder cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aurealis Therapeutics company profile →
Admune Therapeutics
HQ: United States
Website
- Description: Provider of development and delivery of cytokine therapy drugs for cancer as a clinical-stage biotech company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Admune Therapeutics company profile →
Cleveland Diagnostics
HQ: United States
Website
- Description: Provider of efficacious, affordable cancer diagnostic tests, including IsoPSA, a blood test designed to improve the accuracy of prostate cancer detection and reduce unnecessary biopsies by distinguishing cancer-related PSA proteins, and the Solvent Interaction Analysis Platform, which measures structural differences in proteins to identify cancer biomarkers and facilitate development of blood tests for cancer diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cleveland Diagnostics company profile →
Hybrigenics
HQ: France
Website
- Description: Provider of bioinformatics platforms to identify, validate, and inhibit protein interactions to develop cancer therapeutics; a biopharmaceutical company focused on R&D of new targets and therapies against cancer, researching deubiquitinating enzymes (DUBs), and having stopped development of inecalcitol, a vitamin D receptor agonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hybrigenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theraclone Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theraclone Sciences
2.2 - Growth funds investing in similar companies to Theraclone Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theraclone Sciences
4.2 - Public trading comparable groups for Theraclone Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →